T-cell Activation: Mechanisms, Dysfunction, Therapy

Akira Fujimoto^*
*Correspondence: Akira Fujimoto, Department of Immunogenetics, Shizuoka Advanced Science University, Shizuoka, Japan, Email:

Introduction

The intricate process of T-cell activation is central to effective adaptive immunity, starting with the T-cell receptor (TCR) and CD3 complexes. These foundational molecular architectures are responsible for the critical first steps of signal initiation and transmission, occurring immediately following antigen recognition. This involves dynamic structural changes and a cascade of downstream signaling events, all of which are essential to kick off the comprehensive activation of T cells, setting the stage for subsequent immune responses [1].

During activation and differentiation, T cells undergo a dramatic and essential metabolic reprogramming. This isn't merely a consequence but an integral part of their fate decisions. Specific metabolic pathways, such as heightened glycolysis and robust oxidative phosphorylation, are engaged to fuel the rapid proliferation required for an effective immune response and to support their diverse effector functions [2].

Beyond the initial recognition, T-cell activation is governed by complex and interconnected signaling networks. These networks involve not only the TCR but also crucial co-stimulatory receptors and various cytokine receptors. These diverse signals converge, orchestrating a precise regulation of gene expression, cellular proliferation, and the eventual effector functions of the T cell. This intricate cascade transforms a simple recognition event into a powerful and targeted functional immune response [3].

The principles of T-cell activation find a powerful practical application in Chimeric Antigen Receptor (CAR) T-cell therapy. Here, genetically engineered CAR T cells are designed to activate, mirroring and diverging from natural T-cell activation. Their specific signaling domains are engineered to drive robust T-cell proliferation, potent cytotoxicity against target cells, and the controlled production of cytokines. Understanding these underlying mechanisms is crucial for appreciating their clinical efficacy in cancer therapy and for addressing ongoing challenges [4].

A unique facet of T-cell biology involves regulatory T cells (Tregs), which operate as the immune system's 'brakes.' Their activation is distinct, requiring specific signaling requirements and transcriptional programs that set them apart from effector T cells. These unique pathways enable Tregs to exert their critical suppressive functions, playing a vital role in maintaining immune homeostasis and preventing detrimental autoimmunity [5].

The performance of T cells, much like sophisticated software, is dictated by epigenetic regulation. This involves dynamic modifications such as DNA methylation, histone modifications, and the influence of non-coding RNAs. These epigenetic changes are not static; they actively regulate gene expression, thereby controlling key aspects of T-cell differentiation, their proliferative capacity, and their ultimate effector responses. This layer of control ensures T cells can adapt and perform their roles precisely [6].

The initiation of adaptive immunity critically depends on antigen-presenting cells (APCs), particularly dendritic cells, which orchestrate T-cell activation. APCs perform the crucial 'initial handshake' by efficiently capturing, processing, and presenting antigens. Concurrently, they provide essential co-stimulatory signals, which together are vital for effectively priming naive T cells and shaping the overall adaptive immune responses [7].

However, sustained T-cell responses face challenges, including T-cell exhaustion. This state of dysfunction often emerges during chronic infections and in the context of cancer. It is characterized by persistent antigen exposure and inflammatory signals that induce distinct epigenetic and transcriptional changes. These alterations ultimately impair T-cell effector functions, highlighting the delicate and critical balance required between effective activation and the onset of exhaustion [8].

When T-cell activation deviates from its normal course, it can lead to severe consequences, as seen in various autoimmune diseases. Here, aberrant T-cell activation patterns are observed, often driven by a combination of genetic predispositions, environmental triggers, and dysregulated signaling pathways. This breakdown of self-tolerance results in pathogenic T-cell responses, and understanding these specific activation pathways is key to developing emerging therapeutic strategies [9].

Our ability to unravel the complexities of T-cell activation is significantly advanced by 'omics' technologies. High-throughput methods such as genomics, transcriptomics, and proteomics provide comprehensive insights into the molecular changes that occur during T-cell responses. These powerful tools enable the identification of novel biomarkers and potential therapeutic targets, continuously revolutionizing our understanding of this intricate biological process [10].

Description

T-cell activation represents a pivotal event in adaptive immunity, initiated by the precise interaction of the T-cell receptor (TCR) and CD3 complexes with antigens. This initial recognition triggers a cascade of structural changes and downstream signaling events, fundamentally kicking off T-cell activation [1]. These intricate signaling networks extend beyond the TCR, encompassing co-stimulatory and cytokine receptors. Their convergence orchestrates gene expression, proliferation, and effector functions, translating antigen recognition into a fully functional immune response [3].

A crucial aspect of T-cell function is the profound metabolic reprogramming that occurs upon activation and differentiation. T cells dynamically shift their metabolic pathways, relying on processes like glycolysis and oxidative phosphorylation to fuel their rapid proliferation and specialized effector functions. This metabolic shift is not merely a byproduct, but an integral component driving T-cell fate decisions [2]. Moreover, the 'software' governing T-cell activation and function involves dynamic epigenetic regulation. DNA methylation, histone modifications, and non-coding RNAs actively control gene expression, influencing T-cell differentiation, proliferation, and effector responses [6].

The orchestration of T-cell activation primarily falls to antigen-presenting cells (APCs), particularly dendritic cells. These key players capture, process, and present antigens, simultaneously delivering essential co-stimulatory signals. This crucial 'initial handshake' effectively primes naive T cells and shapes the adaptive immune response [7]. Building on these fundamental principles, Chimeric Antigen Receptor (CAR) T cells represent a powerful therapeutic application. Their design incorporates specific signaling domains to drive T-cell proliferation, cytotoxicity, and cytokine production, demonstrating how activation principles are leveraged for clinical efficacy in cancer therapy [4].

Beyond effector functions, immune homeostasis is critically maintained by regulatory T cells (Tregs). Their activation is distinct, characterized by unique signaling requirements and transcriptional programs that enable their suppressive functions. Tregs act as the immune system's 'brakes,' preventing autoimmunity and ensuring a balanced immune response [5].

However, T-cell responses are not without their challenges. Persistent antigen exposure in chronic infections and cancer can lead to T-cell exhaustion, a state of dysfunction marked by distinct epigenetic and transcriptional changes that impair effector functions. This highlights the delicate balance between sustained activation and the onset of dysfunction [8]. Furthermore, aberrant T-cell activation is a hallmark of autoimmune diseases. Genetic predispositions, environmental factors, and dysregulated signaling pathways contribute to the breakdown of self-tolerance, leading to pathogenic T-cell responses. Understanding these dysregulated pathways is crucial for developing novel therapeutic strategies [9].

Our comprehension of T-cell activation continues to evolve, significantly aided by advanced 'omics' technologies. Genomics, transcriptomics, and proteomics offer high-throughput methods that provide comprehensive insights into the molecular changes occurring during T-cell responses. These powerful tools are instrumental in identifying novel biomarkers and therapeutic targets, revolutionizing the study of this complex biological process [10].

Conclusion

T-cell activation is a complex process crucial for adaptive immunity, starting with the T-cell receptor (TCR) and CD3 complexes initiating signals upon antigen recognition, leading to structural changes and downstream signaling. Activated T cells undergo significant metabolic reprogramming, shifting to pathways like glycolysis and oxidative phosphorylation to support rapid proliferation and effector functions, showing metabolism is key to cell fate. Intricate signaling networks, involving TCR, co-stimulatory, and cytokine receptors, converge to regulate gene expression, proliferation, and effector functions, translating recognition into a functional immune response. Chimeric Antigen Receptor (CAR) T cells offer a practical application of activation principles, where engineered signaling domains drive proliferation, cytotoxicity, and cytokine production, linking to their clinical efficacy in cancer therapy. Regulatory T cells (Tregs) have unique activation requirements and transcriptional programs that differentiate them from effector T cells, enabling their suppressive functions to maintain immune homeostasis and prevent autoimmunity. Epigenetic mechanisms, including DNA methylation and histone modifications, dynamically regulate gene expression to control T-cell differentiation, proliferation, and effector responses, acting as the 'software' for T-cell roles. Antigen-presenting cells (APCs), especially dendritic cells, are critical orchestrators of T-cell activation, capturing and presenting antigens while providing co-stimulatory signals to prime naive T cells and shape adaptive responses. T-cell exhaustion, a state of dysfunction in chronic infections and cancer, arises from persistent antigen exposure and inflammatory signals, leading to epigenetic and transcriptional changes that impair effector functions. Aberrant T-cell activation contributes to autoimmune diseases, where genetic predispositions and dysregulated signaling pathways break self-tolerance, leading to pathogenic responses and informing therapeutic strategies. Omics technologies provide comprehensive insights into T-cell activation, revealing molecular changes during responses and aiding in identifying novel biomarkers and therapeutic targets.

Acknowledgement

None

Conflict of Interest

None

References

Balbino A, Tatiana M, Juan AP. "The TCR and CD3 complexes: an integrated view of signal initiation and transmission".Immunol Rev 302 (2021):33-47.

Indexed at, Google Scholar, Crossref

Wenzhao Z, Emily CO, Si M. "Metabolic reprogramming of T cells during activation and differentiation".Cell Mol Immunol 19 (2022):806-819.

Indexed at, Google Scholar, Crossref

Stephanie MK, Sarah EO, Joseph AN. "Signaling pathways in T cell activation".J Leukoc Biol 109 (2021):725-738.

Indexed at, Google Scholar, Crossref

Andrew H, Yufei L, Chunjing L. "CAR T Cell Activation: From Basic Mechanisms to Clinical Outcomes".Cancers (Basel) 12 (2020):2775.

Indexed at, Google Scholar, Crossref

Emiko N, Yosuke I, Yoshihiro M. "Regulatory T Cell Activation and Suppressive Mechanisms".J Clin Immunol 41 (2021):989-1002.

Indexed at, Google Scholar, Crossref

Si C, Yan Z, Songwei Y. "Epigenetic Regulation of T Cell Activation and Function".Front Immunol 12 (2021):649366.

Indexed at, Google Scholar, Crossref

Caetano ReS, Ira M, Antonio L. "Antigen-Presenting Cells: Key Players in T-Cell Activation and Immune Regulation".Immunity 54 (2021):1621-1634.

Indexed at, Google Scholar, Crossref

Stephanie DB, E JW, Sarah KD. "Molecular mechanisms of T cell exhaustion in chronic infections and cancer".Immunity 53 (2020):689-703.

Indexed at, Google Scholar, Crossref

Lucienne C, Jean-François B, Sylvie Y. "T-cell activation in autoimmune diseases: novel insights and therapeutic strategies".Nat Rev Rheumatol 17 (2021):405-420.

Indexed at, Google Scholar, Crossref

David G, Sadegh G, Giovanni L. "Omics technologies for unraveling T cell activation and function".Curr Opin Immunol 65 (2020):7-14.

Indexed at, Google Scholar, Crossref